Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant

Journal of Controlled Release

Volumn 120, Issue 1-2, 2007, Pages 4-10

  Kim, Sang Kyoon ^a   Lee, Dong Yun ^b   Lee, Eunhye ^a   Lee, Yong kyu ^c   Kim, Choong Yong ^d   Moon, Hyun Tae ^e   Byun, Youngro ^b,e  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b Seoul National University   (South Korea)

^c Chungju National University   (South Korea)

^d Korea Research Institute of Chemical Technology   (South Korea)

^e Mediplex Corporation   (South Korea)

Author keywords

Anti coagulant; Deoxycholic acid; Low molecular weight heparin; Oral absorption

Indexed keywords

DEOXYCHOLIC ACID; HEPARIN; ORAL ABSORPTION;

COAGULATION; DIMETHYL SULFOXIDE; INSULIN; MACROMOLECULES; ORGANIC ACIDS;

DRUG PRODUCTS;

ANTICOAGULANT AGENT; DEOXYCHOLIC ACID CONJUGATED HEPARIN; DEOXYCORTICOSTERONE ACETATE; DIMETHYL SULFOXIDE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG FORMULATION; DRUG PENETRATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CHEMISTRY, PHARMACEUTICAL; DEOXYCHOLIC ACID; DIFFUSION; DIMETHYL SULFOXIDE; FACTOR XA; FEASIBILITY STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; ILEUM; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; JEJUNUM; MACACA FASCICULARIS; MALE; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; SOLUBILITY; SOLVENTS; SYMPORTERS; TAUROCHOLIC ACID;

EID: 34249914210     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.03.008     Document Type: Article

References (18)

1. Landefiled C.S., and Hanus P. Economic burden of venous thromboembolism. In: Goldhaber S.Z. (Ed). Prevention of Venous Thromboembolism (1993), Marcel Dekker, New York 69-85
2. Alpert J.S., and Dalen J.E. Epidemiology and natural history of venous thromboembolism. Prog. Cardiovasc. Dis. 36 (1994) 417-422
3. Hull R., Delmore T., Genton E., Hirsh J., Gent M., Sackett D., McLoughlin D., and Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N. Engl. J. Med. 301 (1979) 855-858
4. Hyers T.M., Hull R.D., and Weg J.G. Antithrombotic therapy for venous thromboembolic disease. Chest 108 (1995) 335S-351S (suppl)
5. Hull R., Delmore T., Carter C., Hirsh J., Genton E., Gent M., Turpie G., and McLaughlin D. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N. Engl. J. Med. 306 (1982) 189-194
6. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., and Gilman A.G. The Pharmacological Basis of Therapeutics vol. 9 (1996), McGraw-Hill, New York
7. Gonze M.D., Salartash K., Sternbergh III W.C., Baughman R.A., Leone-Bay A., and Money S.R. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation 101 (2000) 2658-2661
8. Welt F.G.P., Woods T.C., and Edelman E.R. Oral heparin prevents neointimal hyperplasia after arterial injury. Inhibitory potential depends on type of vascular injury. Circulation 104 (2001) 3121-3124
9. Baughman R.A., Kapoor S.C., Agarwal R.K., Kisicki J., Catella-Lawson F., and FitzGerald G.A. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation 98 (1998) 1610-1615
10. Jiao Y., Ubrich N., Hoffart V., Marchand-Arvier M., Vigneron C., Hoffman M., and Maincent P. Anticoagulant activity of heparin following oral administration of heparin-loaded microparticles in rabbits. J. Pharm. Sci. 91 (2002) 760-768
11. Lee Y., Moon H.T., and Byun Y. Preparation of slightly hydrophobic heparin derivatives which can be used for solvent casting in polymeric formulation. Thromb. Res. 92 (1998) 149-156
12. Lee Y., Kim S.H., and Byun Y. Oral delivery of new heparin derivatives in rats. Pharm. Res. 17 (2000) 1259-1264
13. Lee Y., Nam J.H., Shin H., and Byun Y. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulation agent. Circulation 104 (2001) 3116-3120
14. Kramer W., Corsiero D., and Fredrich M. Intestinal absorption of bile acids: paradoxical behavior of the 14 kDa ileal lipid-binding protein in differential photoaffinity labeling. Biochem. J. 333 (1998) 335-341
15. Kramer W., Wess G., and Enhen A. Modified bile acids as carriers for peptides and drugs. J. Control. Release 46 (1997) 17-30
16. Kim S., Vaishali B., Lee E., and Byun Y. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb. Res. 117 (2006) 419-427
17. Hidalgo I.J., and Borchardt R.T. Transport of bile acids in human intestinal epithelial cell line Caco-2. Biochim. Biophys. Acta 1035 (1990) 97-103
18. Chandler C.E., Zaccaro L.M., and Moberly J.B. Transepithelial transport of cholyltaurine by Caco-2 cell monolayers is sodium dependent. Am. J. Physiol. 264 (1993) G1118-G1125